Orexo acquires exclusive US rights for commercialization of deprexis®
Category: #healthcare  By Mateen Dalal  Date: 2020-05-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Orexo acquires exclusive US rights for commercialization of deprexis®

Orexo, a renowned Sweden based pharmaceutical company, has reportedly announced that it acquired the exclusive rights to commercialize GAIA AG’s digital therapy solution, deprexis®, in the U.S. Deprexis is a digital treatment platform to help individuals manage the symptoms of depression. The platform is also among the most researched digital treatments across the globe.

The acquisition of the commercialization rights by Orexo follows two previous deals with GAIA in which Orexo procured the exclusive US rights for vorvida®, and OXD01. Vorvida is scientifically proven to decrease risky drinking patterns among adults having AUD (alcohol use disorder). Meanwhile, OXD01 is a novel digital treatment that is currently being developed to treat OUD (opioid use disorder).

The demand for digital therapies owing to the COVID-19 crisis is rapidly increasing. The COVID-19 crisis, along with the steps that are being taken to restrict its spread, is projected to cause a tremendous rise in cases of mental illnesses like substance abuse and depression.

 Orexo is well-positioned to be at the forefront of addressing this rise in mental illnesses by providing digital therapies that boast of efficacy that is scientifically proven, allowing patients to get help while subsequently adhering to social distancing practices.

The emergency use authorization policy unveiled recently by the US FDA (Food and Drug Administration) to address Psychiatric disorders through digital health devices would enable the company to expedite the launch of these three treatments in 2020 to effectively help society tackle some of the negative effects of the coronavirus pandemic.

As per the terms of the agreement, GAIA would receive an upfront payment and would also get royalties on the basis of net sales starting for January 1, 2022. Deprexis is already FDA classified and the company expects to rollout deprexis® across the United States in the summer of 2020.   

 

Source credit: https://orexo.com/media/regulatory-press-releases?releaseId=9CC5F2D2BF210584

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Ampio starts phase 1 clinical trial of Ampion for Covid-19 patients
Ampio starts phase 1 clinical trial of Ampion for Covid-19 patients
By Mateen Dalal

Ampio Pharmaceuticals Inc., the U.S-based biopharmaceutical firm focused on the development of novel...

Eon to use linguistics model to identify IPN and manage lung cancer
Eon to use linguistics model to identify IPN and manage lung cancer
By Mateen Dalal

Eon, a healthcare technology company, has announced the expansion of its data science models. The mo...

AE Industrial Acquires PCI; Adds New Government Tech Investment
AE Industrial Acquires PCI; Adds New Government Tech Investment
By Mateen Dalal

AE Industrial Partners (AEI), a private equity firm specializing in Defense, Aerospace & Governm...